Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?

Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Chakrabarti, S, Hale, G, Waldmann, H
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2004

Gelijkaardige items

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
door: Watson, C, et al.
Gepubliceerd in: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
door: Hale, G, et al.
Gepubliceerd in: (2002)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
door: Phuong-Thu T Pham, et al.
Gepubliceerd in: (2008-12-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
door: Hale, G, et al.
Gepubliceerd in: (1988)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
door: Clatworthy, MR, et al.
Gepubliceerd in: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
door: Watson, C, et al.
Gepubliceerd in: (2005)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
door: Potter, M, et al.
Gepubliceerd in: (2000)

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go
door: Lv Meng, et al.
Gepubliceerd in: (2012-03-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
door: Fibbe, W, et al.
Gepubliceerd in: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
door: Hale, G, et al.
Gepubliceerd in: (2001)

Where do we go from here?
door: Rai, Vijesh
Gepubliceerd in: (2016)

Expert Systems: Where Are We? And Where Do We Go from Here?
door: Davis, et al.
Gepubliceerd in: (2004)

Editorial: Where Are We Now and Where Do We Go From Here
door: Gabriele Manganaro
Gepubliceerd in: (2022-01-01)

Availability of Campath-1 antibodies for bone marrow transplantation.
door: Hale, G, et al.
Gepubliceerd in: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
door: Hale, G, et al.
Gepubliceerd in: (1994)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
door: Maria Kadma da Silva Carriço, et al.
Gepubliceerd in: (2003-06-01)

Tractography: where do we go from here?
door: Jbabdi, S, et al.
Gepubliceerd in: (2011)

Afterword: Where Do We Go from Here?
door: Kimberly Vinall, et al.
Gepubliceerd in: (2017-01-01)

Transplantation tolerance: the big picture. Where do we stand, where should we go?
door: Waldmann, H
Gepubliceerd in: (2017)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
door: Cull, G, et al.
Gepubliceerd in: (1999)

Commentary: Retinoblastoma management–Where are we and where do we go from here?
door: P Mahesh Shanmugam
Gepubliceerd in: (2020-01-01)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
door: Lundin, J, et al.
Gepubliceerd in: (2001)

How Did We Get Here and Where are We Going?
door: Georgina CHAMBERS
Gepubliceerd in: (2022-09-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
door: Russell, N, et al.
Gepubliceerd in: (1999)

CAMPATH-1H in inflammatory arthritis.
door: Watts, R, et al.
Gepubliceerd in: (1993)

COVID-19 - where do we go from here?
door: Lee, Pei Hua, et al.
Gepubliceerd in: (2020)

Propriospinal myoclonus: where do we go from here?
door: Brown, P
Gepubliceerd in: (2014)

Oil prices : where do we go from here?/
door: 284295 Zanoyan, Vahan
Gepubliceerd in: (1986)

Math anxiety : where do we go from here? /
door: 297422 Hunt, Glen E.

Advanced ceramics : where do we go from here?/
door: 348668 Smith, Vincent, et al.

Multiple Sclerosis: Where do we go from here?
door: Marta Tejera-Alhambra, et al.
Gepubliceerd in: (2016-07-01)

Calibration research: Where do we go from here?
door: Linda eBol, et al.
Gepubliceerd in: (2012-07-01)

PITUITARY INCIDENTALOMAS – WHERE DO WE GO FROM HERE?
door: Syed Ali Imran
Gepubliceerd in: (2016-08-01)

Developmental Dyslexia: Where Do We Go from Here?
door: Paul E. Engelhardt
Gepubliceerd in: (2020-03-01)

OMR At Crossroads; Where Do We Go From Here ?
door: Mangala Meti
Gepubliceerd in: (2004-01-01)

Topological photonics: Where do we go from here?
door: Segev Mordechai, et al.
Gepubliceerd in: (2020-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
door: Chakrabarti, S, et al.
Gepubliceerd in: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
door: Kottaridis, P, et al.
Gepubliceerd in: (2001)

CAMPATH: from concept to clinic.
door: Waldmann, H, et al.
Gepubliceerd in: (2005)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
door: Cull, G, et al.
Gepubliceerd in: (2000)